Latigo Biotherapeutics
LTGO

Latigo Biotherapeutics (LTGO) stock price, chart and financials

Price chart

−19.12% over 1Y
Aug 7, 2026Low $14.00 · High $25.00Oct 15, 2026

Company profile

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Frequently asked questions

  • How do I buy stock in Latigo Biotherapeutics (LTGO)?

    LTGO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.